Health care and medical treatment services have now quickly evolved into a more innovative and efficient practice that provides clients with better options. With the relative breakthroughs and advancements in technology, the industry of medicine has greatly improved in diverse aspects of study and practice. Almost any health condition or illness can now be rapidly identified even before it arises thus necessary preventive measures are provided to reduce the effects. In the industry of acute pain and surgical pain management, a new discovery has been made, namely the COX-2 Specific or Selective Inhibitors. So what is COX-2 Specific Inhibitors and how does it work?
Basically, a COX-2 selective inhibitor is a type of NSAID, or non-steroidal anti-inflammatory drug, which primarily targets COX-2 as the name implies. COX-2 is an enzyme which is responsible for pain and inflammation. Focusing selectivity for COX-2 lowers the potential for peptic ulceration, and is the primary attribute for celecoxib, rofecoxib and other consituents of this drug category. COX-2 selectivity doesn’t quite seem to lower other adverse effects of non-steroidal anti-inflammatory drugs, most noticeably a high risk for renal failure, and some outcomes have displayed an elevation in the risk for other complications, including stroke, thrombosis, and heart attack by a relative elevation in thromboxane.
Although it is a promising drug for acute pain and surgical pain relief and treatment, there are several dangers and adverse effects that COX-2 specific inhibitors have. And one of the most notable risks is concerned with the cardiovascular condition of the patient. However, this isn’t surprising at all as prostaglandins are included in management of blood pressure by the client’s kidneys. Thus, cardiovascular effects of non-steroidal anti-inflammatory drugs are prescribed for arthritis inflammation and pain required to be considered when selecting the proper medication for each patient case.
The future of COX-2 inhibitors is still unclear yet may prove to be promising, especially in studies and effective treatment of Neuroblastomas, Cancer and other targets. The restriction of COX-2 is cardinal for the anti-inflammatory and analgesic applications of the specific COX-2 inhibitor celecoxib, and somewhat likely also for its capabilities in avoiding the growth of cancer.
imagecredit: © lu-photo – Fotolia.com